Here’s the fast answer: your testosterone counts as clinically low when a blood test shows total testosterone consistently under 300 ng/dL, confirmed on at least two separate early-morning draws, and you also have symptoms that go with it. That’s the American Urological Association’s line in the sand [2]. Not a single number pulled from one lab slip. Not a vibe. A repeated, time-of-day-specific measurement plus symptoms, together.
That answer matters more than it sounds like it should, because almost every fight in this space, marketing claims, provider quality, whether a clinic is trustworthy, traces back to whether that number was actually checked. So before wading into safety data or dosing or cost, it helps to sit with this one figure for a second, because everything else in this piece answers a question that flows from it.
Wait, why does it matter what time of day the blood was drawn?
Because testosterone isn’t flat throughout the day. It peaks in the early morning and drifts down as the day goes on, so a man tested at 4 p.m. can register “low” even though his actual level is completely ordinary. That’s why the guideline insists on morning draws, and why it insists on two of them rather than one [2]. The Endocrine Society backs this up from its own angle, telling clinicians to diagnose hypogonadism only when a man has both symptoms and testosterone that’s unequivocally, consistently low, not just one number on one day [3].
Put those two guidelines side by side and you get a simple filter: number plus symptoms plus repetition plus correct timing. Any one of those missing, and what you have isn’t a diagnosis. It’s a guess. This turns out to be the single easiest way to judge a testosterone provider, too, which is the thread this piece keeps pulling on.
Okay, but is testosterone therapy actually dangerous for your heart?
This is the question that hung over the field for roughly a decade, and it finally has a real answer instead of a rumor. The TRAVERSE trial randomized more than 5,000 middle-aged and older men who had hypogonadism and either existing heart disease or high risk for it, split them between testosterone and placebo, and tracked major cardiac events. The result: testosterone was noninferior to placebo, meaning it did not cause the excess of heart attacks, strokes, and cardiovascular deaths that everyone had been bracing for [4].
That’s the good half. Here’s the half that gets left out of a lot of marketing copy: the same trial found higher rates of certain other problems in the testosterone group, including pulmonary embolism, atrial fibrillation, and acute kidney injury [4]. So the full, honest answer is two-sided. No, it doesn’t appear to raise your risk of the big cardiac events researchers feared most, in men who were actually eligible for the trial. Yes, there are specific risks that showed up and are worth monitoring. If a provider only tells you the reassuring half, ask what they left out.
So what does testosterone therapy actually do for a man who qualifies?
The clearest data on this comes from the Testosterone Trials, a set of placebo-controlled studies in men 65 and older whose testosterone was confirmed under 275 ng/dL along with symptoms. What improved, reliably and measurably, was sexual function: more sexual activity, more desire, better erectile function than placebo [5]. That part held up.
What didn’t hold up nearly as well were the bigger promises. Physical function and general vitality moved, but only modestly and less consistently, things like walking ability and energy [5]. So if the pitch you’re hearing sounds like a full-body reset, more muscle, boundless energy, a decade rolled back, that’s not what the strongest trial in this area actually found. The realistic version is narrower: better sexual function for a correctly diagnosed man, and smaller, less dependable gains elsewhere.
What dose should I actually be on?
This is where the gap between what’s marketed and what’s medically sound gets widest, so it deserves a straight answer: there isn’t a single dose that applies to you, because the entire goal of replacement therapy is to bring a deficient man back into a normal range and keep him there, confirmed by follow-up labs. The most common injectable forms in US practice, testosterone cypionate and testosterone enanthate, are long-acting by design, meant to hold a normal physiologic level rather than push past it.
That’s the real dividing line between treatment and misuse. Replacement dosing aims at normal and gets checked with blood work. The much higher doses tied to physique or performance goals aren’t replacement at all, they’re the exact scenario the diagnostic guidelines exist to head off, and they carry real downside without treating an actual deficiency. One more detail worth knowing if fertility is part of your plans: the Endocrine Society specifically recommends against starting testosterone in men trying to conceive soon, since it can suppress the body’s own hormone production and shut down sperm production [3]. The particular ester, milligram amount, and injection schedule are decisions for a clinician working from your labs, not a number handed out before any blood has been drawn.
Is testosterone therapy even FDA-approved for “getting older”?
No, and this is probably the most misunderstood figure in the entire category. Prescription testosterone is FDA-approved as replacement therapy for men whose hypogonadism comes from an identifiable medical cause, something affecting the testicles, pituitary, or brain. In 2015 the FDA went further and specifically warned that benefit and safety have not been established for low testosterone caused simply by aging, and required label changes saying so, alongside a warning about possible increased heart attack and stroke risk [1].
That doesn’t mean an older man with genuinely low levels and real symptoms can’t be treated thoughtfully, that happens all the time, and often off-label. It means the honest way to describe it is “this might be appropriate for you off-label, after a real diagnosis,” never “testosterone is approved to fix aging.” If an ad implies the second version, it’s overselling the first.
How do you actually tell a good provider from a bad one?
Here’s the reframe worth carrying out of this piece: instead of a long checklist, think of it as three exams a provider has to pass, in order, before you should trust them with a prescription.
Exam one, the diagnosis exam. Did they require total testosterone under 300 ng/dL, confirmed on two morning draws, alongside real symptoms [2]? Or did they diagnose off one afternoon number, or worse, a quiz with no blood work at all?
Exam two, the safety exam. Can they explain TRAVERSE accurately, more than 5,000 men, noninferior on the big cardiac outcomes, but with higher rates of pulmonary embolism and atrial fibrillation [4]? A provider who only recites the reassuring half failed this exam even if they got the headline right.
Exam three, the honesty exam. Do they describe the benefit as it actually shows up in the data, reliable sexual-function improvement, smaller and less consistent gains elsewhere [5], and do they call an aging-related prescription what it is, off-label, not FDA-approved for that use [1]? Or do they sell you a total-transformation story the trials never supported?
A provider that passes all three is practicing medicine. One that can’t produce answers to these questions, no matter how polished the marketing, is running a funnel with a needle at the end of it.
Where does supervised access actually fit into this?
Every figure above points at the same structural requirement: someone has to check you against the threshold, a licensed pharmacy has to fill the prescription, and monitoring has to continue after the first box arrives. That structure, not a slogan, is the actual product. FormBlends is one provider organized around exactly that, physician evaluation, lab work, a prescription only where it fits, and dispensing through licensed 503A compounding pharmacies. The medication itself sits in a low cash-pay range there, roughly $30 to $100 a month depending on the ester, with the surrounding program, evaluation and monitoring, making up the rest.
Worth saying plainly: compounded testosterone isn’t an FDA-approved finished product, so even a well-run supervised program can’t make TRT risk-free, and it can’t make it right for every man who wants it. What a good supervised model actually buys you is the diagnosis, the sourcing, and the follow-up, not a stamp of approval it doesn’t hold.
Questions people actually ask
What testosterone number counts as “low”? Total testosterone consistently under 300 ng/dL is the American Urological Association’s threshold, but the number by itself isn’t a diagnosis. It needs confirmation across at least two separate early-morning draws, in a man who also has symptoms of deficiency. One reading, an afternoon draw, or a low number with no symptoms doesn’t clear the bar [2].
Why does the blood draw have to happen in the morning? Testosterone follows a daily rhythm, peaking early and drifting down through the day, so an afternoon draw can flag a perfectly normal man as low. Drawing in the morning, twice, is how the guideline screens out that daily swing before anyone calls it a diagnosis. A provider working off one afternoon number is reading the wrong figure [2].
Does testosterone therapy cause heart attacks? In appropriately selected men with hypogonadism, the more-than-5,000-person TRAVERSE trial found testosterone was noninferior to placebo for major cardiac events, meaning it didn’t produce the excess heart attacks, strokes, and cardiovascular deaths people worried about. That same trial reported higher rates of certain other events, including pulmonary embolism and atrial fibrillation, so the complete answer includes both: no excess on the main cardiovascular measure, with specific risks worth watching [4].
What does TRT actually improve? The most reliable, measurable gain across the trial data is sexual function, more activity, more desire, better erectile function than placebo, in men who were correctly diagnosed. Effects on physical function, energy, and mood were smaller and less consistent. The sweeping total-transformation claims are exactly where the strongest trials come up short, so the realistic expectation is improved sexual function, not a reversed clock [5].
Is testosterone FDA-approved for low testosterone from aging? No. It’s approved as replacement for men whose hypogonadism traces to an identifiable medical cause affecting the testicles, pituitary, or brain. The FDA specifically cautioned in 2015 that benefit and safety haven’t been established for aging-related low testosterone alone. A clinician can still treat an older man with genuinely low, confirmed levels and real symptoms, but that’s off-label care after a real workup, not an approved fix for aging [1].
How much does the testosterone medication cost through a supervised program? Through a supervised model like FormBlends, the medication itself runs roughly $30 to $100 a month depending on the ester, with the clinician evaluation, lab work, and ongoing monitoring making up the rest of the program cost. The caveat worth keeping in mind: compounded testosterone isn’t an FDA-approved finished product, so a well-run program still can’t promise zero risk or guarantee it’s the right call for every man.
References
- U.S. Food and Drug Administration. “FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use.” March 3, 2015. States that prescription testosterone is approved for men with low testosterone caused by certain medical conditions, that benefit and safety have not been established for low testosterone due to aging, and requires labeling on possible cardiovascular risk. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due
- Mulhall JP, Trost LW, Brannigan RE, et al. “Evaluation and Management of Testosterone Deficiency: AUA Guideline.” J Urol. 2018 Aug;200(2):423-432. PMID 29601923. Sets the diagnostic standard of total testosterone consistently below 300 ng/dL on at least two early-morning measurements, in a man with symptoms. https://pubmed.ncbi.nlm.nih.gov/29601923/
- Bhasin S, Brito JP, Cunningham GR, et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. PMID 29562364. Recommends diagnosing hypogonadism only in men with both symptoms and unequivocally and consistently low testosterone, and recommends against starting testosterone in men planning fertility in the near term.
- Lincoff AM, Bhasin S, Flevaris P, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” N Engl J Med. 2023 Jul 13;389(2):107-117. PMID 37326322. The TRAVERSE trial, more than 5,000 men with hypogonadism and cardiovascular risk; testosterone was noninferior to placebo for major adverse cardiac events, with higher rates of certain events including pulmonary embolism and atrial fibrillation.
- Snyder PJ, Bhasin S, Cunningham GR, et al. “Effects of Testosterone Treatment in Older Men.” N Engl J Med. 2016 Feb 18;374(7):611-624. PMID 26886521. The Testosterone Trials in men 65 and older with confirmed low testosterone; testosterone improved sexual function consistently, with smaller and less consistent effects on physical function and vitality.
How low does testosterone have to be for treatment to make sense?
Most guidelines land on a total testosterone under 300 ng/dL as the point where treatment becomes a reasonable conversation, but the number alone won’t settle it. Labs need to be drawn fasting, in the morning, on two separate days before a diagnosis holds up. Symptoms carry just as much weight as the number itself, so a man sitting at 280 ng/dL with no symptoms at all is in a genuinely different position than a man at 310 ng/dL who’s exhausted, losing muscle, and dealing with low libido.
What is the most common treatment for low testosterone in men?
Testosterone replacement therapy, typically a daily topical gel, a twice-weekly self-injection, or a long-acting injection given every 10 to 14 weeks, is the standard route for most men with confirmed hypogonadism. Each format comes with real trade-offs: convenience, cost, the risk of skin transfer to a partner, and how steady your levels stay between doses. Some men end up pursuing physician-supervised compounded formulations through pharmacies like FormBlends when the standard commercial options don’t fit their particular situation.
Does insurance typically cover low testosterone treatment?
It varies a lot depending on the plan and the documented reason behind the low reading. Most major insurers will cover treatment when there’s a diagnosed medical cause, a pituitary issue or primary hypogonadism, backed by two low lab values and matching symptoms. Age-related decline with borderline numbers gets denied far more often. It’s worth calling your insurer before you start, and asking specifically whether the delivery method your doctor is recommending, gel versus injection, sits on the formulary.
Can lifestyle changes raise testosterone enough to avoid medication?
For men sitting in the low-normal range, yes, sometimes meaningfully. Consistent resistance training, shedding excess body fat, treating sleep apnea, and cutting back on alcohol can each nudge levels upward, and the research on sleep quality specifically is fairly compelling. That said, if your levels are genuinely in hypogonadal territory and there’s a structural cause behind it, testicular or pituitary damage, lifestyle changes will still help your overall health, but they’re unlikely to close the gap enough to resolve symptoms on their own.
